Increased urinary excretion of interleukin-17 in nephrotic patients

被引:29
|
作者
Matsumoto, K
Kanmatsuse, K
机构
[1] Saitama Prefectural Univ, Dept Med Technol, Coll Med Sci, Koshigaya, Saitama 3438540, Japan
[2] Nihon Univ, Sch Med, Dept Internal Med 2, Tokyo 173, Japan
关键词
minimal-change nephrotic syndrome; IgA nephropathy; nephrotic syndrome; T cells; interleukin-17;
D O I
10.1159/000058399
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background/Aim:Interleukin (IL)-17 is a newly discovered cytokine that is secreted by activated memory CD4+T cells and modulated the early stage of immune response. To elucidate the pathophysiology of minimal-change nephrotic syndrome (MCNS), we focused on IL-17, which is one of the key factors in regulating an inflammatory response, and thus determined the daily excretion of IL-17 in urine. Methods: For this purpose, excretion levels of IL-17 were measured in the urine of patients with MCNS during relapse and remission using a highly sensitive sandwich enzyme-linked immunosorbent assay. The data obtained were compared with levels of daily urinary excretion of IL-17 in patients with IgA nephropathy (IgAN). A group of healthy subjects served as control. In both experimental groups urine levels of IL-17 excretion were plotted against their daily urinary protein excretion. Results:We demonstrated increased levels of IL-17 excretion in the urine of patients with MCNS and IgAN as compared to the non-nephrotic and healthy controls. In MCNS the daily urinary IL-17 (uIL-17) excretion was increased and returned to baseline with remission of the nephrotic syndrome (NS). We also demonstrated a positive correlation between urinary protein excretion and daily uIL-17 excretion. Conclusion: Taken together, these data indicate that uIL-17 excretion is increased during the NS, suggesting the possibility that daily uIL-17 excretion may reflect the disease activity of NS. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:243 / 249
页数:7
相关论文
共 50 条
  • [41] Interleukin-17 in cutaneous leishmaniasis
    Lopez Kostka, S.
    Dinges, S.
    Knop, J.
    Udey, M. C.
    Iwakura, Y.
    von Stebut, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 : 130 - 130
  • [42] Interleukin-17: A Social Cytokine
    Hoogenraad, Casper C.
    Riol-Blanco, Lorena
    CELL, 2020, 181 (03) : 517 - 519
  • [43] The role of interleukin-17 in epilepsy
    An, Jiayin
    Li, He
    Xia, Demeng
    Xu, Bin
    Wang, Jiayan
    Qiu, Huahui
    He, Jiaojiang
    EPILEPSY RESEARCH, 2022, 186
  • [44] Interleukin-17 in Antifungal Immunity
    Sparber, Florian
    LeibundGut-Landmann, Salome
    PATHOGENS, 2019, 8 (02)
  • [45] Interleukin-17 and airway remodelling
    Lindén, A
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2006, 19 (01) : 47 - 50
  • [47] Interleukin-17 and ischaemic stroke
    Zhang, Qiaohui
    Liao, Yan
    Liu, Zhenquan
    Dai, Yajie
    Li, Yunxin
    Li, Yue
    Tang, Yibo
    IMMUNOLOGY, 2021, 162 (02) : 179 - 193
  • [48] Interleukin-17 and its receptor
    Spriggs, MK
    JOURNAL OF CLINICAL IMMUNOLOGY, 1997, 17 (05) : 366 - 369
  • [49] Interleukin-17 in asthma and COPD
    Linden, A.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 : 36 - 36
  • [50] Interleukin-17 in Inflammatory Myopathies
    Tournadre, Anne
    Miossec, Pierre
    CURRENT RHEUMATOLOGY REPORTS, 2012, 14 (03) : 252 - 256